β-galactosylceramidase (GALC) is a lysosomal enzyme that removes β-galactose from β-galactosylceramide, leading to the formation of the oncosuppressor metabolite ceramide. Recent observations have shown that GALC may exert opposite effects on tumor growth by acting as an oncosuppressive or oncogenic enzyme depending on the different experimental approaches, in vitro versus in vivo observations, preclinical versus clinical findings, and tumor type investigated. This review will recapitulate and discuss the contrasting experimental evidence related to the impact of GALC on the biological behavior of cancer and stromal cells and its contribution to tumor progression.
Belleri, M., Chiodelli, P., Corli, M., Capra, M., Presta, M., Oncosuppressive and oncogenic activity of the sphingolipid-metabolizing enzyme β-galactosylceramidase, <<BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER>>, 2022; 1877 (1): 188675-N/A. [doi:10.1016/j.bbcan.2021.188675] [https://hdl.handle.net/10807/230831]
Oncosuppressive and oncogenic activity of the sphingolipid-metabolizing enzyme β-galactosylceramidase
Chiodelli, Paola;
2022
Abstract
β-galactosylceramidase (GALC) is a lysosomal enzyme that removes β-galactose from β-galactosylceramide, leading to the formation of the oncosuppressor metabolite ceramide. Recent observations have shown that GALC may exert opposite effects on tumor growth by acting as an oncosuppressive or oncogenic enzyme depending on the different experimental approaches, in vitro versus in vivo observations, preclinical versus clinical findings, and tumor type investigated. This review will recapitulate and discuss the contrasting experimental evidence related to the impact of GALC on the biological behavior of cancer and stromal cells and its contribution to tumor progression.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
